Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 35

1.

A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.

Belfort R, Harrison SA, Brown K, Darland C, Finch J, Hardies J, Balas B, Gastaldelli A, Tio F, Pulcini J, Berria R, Ma JZ, Dwivedi S, Havranek R, Fincke C, DeFronzo R, Bannayan GA, Schenker S, Cusi K.

N Engl J Med. 2006 Nov 30;355(22):2297-307.

2.

Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.

Plosker GL, Figgitt DP.

Pharmacoeconomics. 2004;22(6):389-411. Review.

PMID:
15099124
3.

[Steatosis and steatohepatitis in diabetic patient].

Hůlek P, Dresslerová I.

Vnitr Lek. 2011 Apr;57(4):364-7. Review. Czech.

PMID:
21612059
4.

[Insulin sensitizer--anti-diabetic drugs, metformin and pioglitazone that can improve insulin resistance].

Korenaga M, Kawaguchi K, Korenaga K, Uchida K, Sakaida I.

Nihon Rinsho. 2006 Jun;64(6):1157-64. Review. Japanese.

PMID:
16768125
5.

Insulin sensitisers in the treatment of non-alcoholic fatty liver disease: a systematic review.

Shyangdan D, Clar C, Ghouri N, Henderson R, Gurung T, Preiss D, Sattar N, Fraser A, Waugh N.

Health Technol Assess. 2011 Nov;15(38):1-110. doi: 10.3310/hta15380. Review.

6.

Pioglitazone: beyond glucose control.

de Pablos-Velasco P.

Expert Rev Cardiovasc Ther. 2010 Aug;8(8):1057-67. doi: 10.1586/erc.10.98. Review.

PMID:
20670183
7.

The role of thiazolidinediones in non-alcoholic steatohepatitis - a systematic review and meta analysis.

Mahady SE, Webster AC, Walker S, Sanyal A, George J.

J Hepatol. 2011 Dec;55(6):1383-90. doi: 10.1016/j.jhep.2011.03.016. Review.

PMID:
21703200
8.

Therapeutic trials in nonalcoholic steatohepatitis: insulin sensitizers and related methodological issues.

Ratziu V, Caldwell S, Neuschwander-Tetri BA.

Hepatology. 2010 Dec;52(6):2206-15. doi: 10.1002/hep.24042. Review.

PMID:
21105109
9.

Insulin sensitizers in nonalcoholic fatty liver disease and steatohepatitis: Current status.

Stein LL, Dong MH, Loomba R.

Adv Ther. 2009 Oct;26(10):893-907. doi: 10.1007/s12325-009-0072-z. Review.

PMID:
19921118
10.
11.

[PPAR gamma ligand pioglitazone as a therapeutic strategy in nonalcoholic steatohepatitis (NASH)].

Yoneda M, Fujita K, Nakajima A, Wada K.

Nihon Yakurigaku Zasshi. 2006 Oct;128(4):235-8. Review. Japanese. No abstract available.

PMID:
17038787
12.

Safety and tolerability of pioglitazone in high-risk patients with type 2 diabetes: an overview of data from PROactive.

Dormandy J, Bhattacharya M, van Troostenburg de Bruyn AR; PROactive investigators..

Drug Saf. 2009;32(3):187-202. doi: 10.2165/00002018-200932030-00002. Review.

PMID:
19338377
13.

Nonalcoholic fatty liver disease: current issues and novel treatment approaches.

Lomonaco R, Sunny NE, Bril F, Cusi K.

Drugs. 2013 Jan;73(1):1-14. doi: 10.1007/s40265-012-0004-0. Review.

PMID:
23329465
14.

Hepatogenous diabetes. Current views of an ancient problem.

García-Compean D, Jaquez-Quintana JO, Maldonado-Garza H.

Ann Hepatol. 2009 Jan-Mar;8(1):13-20. Review.

PMID:
19221528
15.

Nonalcoholic fatty liver disease and diabetes mellitus: pathogenesis and treatment.

Smith BW, Adams LA.

Nat Rev Endocrinol. 2011 May 10;7(8):456-65. doi: 10.1038/nrendo.2011.72. Review.

PMID:
21556019
16.

[Drug therapy for non-alcoholic steatohepatitis].

Tomita K, Hibi T.

Nihon Rinsho. 2006 Jun;64(6):1146-51. Review. Japanese.

PMID:
16768123
17.

[Nonalcoholic steatohepatitis].

Ratziu V, Tahiri M, Bonyhay L.

Ann Endocrinol (Paris). 2005 Apr;66(2 Pt 2):1S71-80. Review. French.

PMID:
15959406
18.

Insulin resistance in nonalcoholic steatohepatitis: necessary but not sufficient - death of a dogma from analysis of therapeutic studies?

Lonardo A, Bellentani S, Ratziu V, Loria P.

Expert Rev Gastroenterol Hepatol. 2011 Apr;5(2):279-89. doi: 10.1586/egh.11.19. Review.

PMID:
21476922
19.

Thiazolidinediones for nonalcoholic steatohepatitis: A meta-analysis of randomized clinical trials.

He L, Liu X, Wang L, Yang Z.

Medicine (Baltimore). 2016 Oct;95(42):e4947. Review.

20.

Nonalcoholic Fatty liver: a possible new target for type 2 diabetes prevention and treatment.

Fruci B, Giuliano S, Mazza A, Malaguarnera R, Belfiore A.

Int J Mol Sci. 2013 Nov 20;14(11):22933-66. doi: 10.3390/ijms141122933. Review.

Supplemental Content

Support Center